Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101.
Lawrence N. Shulman
No relevant relationships to disclose
Donald A. Berry
Employment or Leadership Position - Berry Consultants
Consultant or Advisory Role - Berry Consultants
Constance T. Cirrincione
No relevant relationships to disclose
Heather Becker
No relevant relationships to disclose
Edith A. Perez
No relevant relationships to disclose
Ruth O'Regan
No relevant relationships to disclose
Silvana Martino
No relevant relationships to disclose
Charles L. Shapiro
No relevant relationships to disclose
James Atkins
No relevant relationships to disclose
Charles Schneider
No relevant relationships to disclose
Gretchen Genevieve Kimmick
Honoraria - CHAMBER Foundation
Research Funding - Bionovo; Bristol-Myers Squibb; GlaxoSmithKline; Wyeth
Other Remuneration - AstraZeneca; Genomic Health; Novartis; Pfizer
Harold J. Burstein
No relevant relationships to disclose
Larry Norton
No relevant relationships to disclose
Hyman Bernard Muss
Consultant or Advisory Role - Pfizer
Clifford Hudis
Research Funding - Merck
Other Remuneration - Estee Lauder Company (I)
Eric P. Winer
No relevant relationships to disclose